SCAB2 Antibody

What is SCARB2 and why is it significant in research?

SCARB2 (Scavenger Receptor Class B Member 2) is a 478 amino acid transmembrane protein with a molecular mass of approximately 54.3 kDa that functions as a type III transmembrane protein belonging to the scavenger receptor family . It serves as a critical lysosomal receptor for glucosylceramidase (GBA1) targeting and is widely expressed across numerous tissue types, including neurons . The protein has achieved particular research significance due to its identification as a functional cellular receptor for Enterovirus 71 (EV71), the causative agent of Hand, Foot, and Mouth Disease (HFMD) that can occasionally lead to severe neurological complications and death . SCARB2 facilitates the complete infection cycle of EV71 by mediating viral attachment to host cells, internalization through clathrin-mediated endocytosis, and critically, the uncoating process that occurs at low pH . The protein's involvement in both normal cellular function and pathological processes makes SCARB2 antibodies essential tools for investigating lysosomal biology, viral pathogenesis, and potential therapeutic interventions.

What are the key structural and functional domains of SCARB2 that antibodies typically target?

SCARB2 possesses a complex three-dimensional structure with distinct domains that serve as important epitopes for antibody binding and functional studies. The protein features a twisted β-barrel core with several α-helices that are critical for its biological functions . The three-helix bundle formed by α-helices 4, 5, and 7 constitutes a putative ligand interaction site and has been identified as particularly important for EV71 binding . Research utilizing chimeric constructs of human and mouse SCARB2 has identified several regions of particular interest for antibody development, including residues 77-113, which contribute significantly to the binding of blocking antibodies like JL2 . The apical region of SCARB2, specifically involving α-helices 2, 5, and 14, has been confirmed through structural studies to serve as a binding interface for antibodies that can inhibit viral infection . Additionally, a highly variable region (HVR) encompassing residues 144-151 has been mapped as critical for the species-specific interaction with EV71, making this region another valuable target for antibodies designed to investigate or disrupt viral entry mechanisms .

How do SCARB2 antibodies differ in their applications compared to antibodies against other scavenger receptors?

SCARB2 antibodies possess distinct research applications that differentiate them from antibodies targeting other scavenger receptor family members due to SCARB2's unique dual functionality in both lysosomal biology and viral pathogenesis. Unlike antibodies against general scavenger receptors that primarily focus on lipid metabolism or phagocytosis, SCARB2 antibodies enable investigations into specialized lysosomal trafficking pathways, particularly for glucosylceramidase enzyme targeting, which has direct implications for Gaucher disease research . SCARB2 antibodies also provide unique opportunities to study viral entry mechanisms for enteroviruses, especially EV71, making them invaluable tools for virology research that cannot be substituted with antibodies against other receptor types . The species-specific variations in SCARB2 structure, particularly between human and mouse variants, enable researchers to develop antibodies that can distinguish between homologs and investigate the molecular basis for species tropism of viral infections . Furthermore, the association of SCARB2 mutations with epilepsy (EPM4) provides a distinctive application for these antibodies in neuroscience research that is not shared with other scavenger receptor antibodies .

What criteria should researchers use when selecting SCARB2 antibodies for specific applications?

Researchers should evaluate several critical factors when selecting SCARB2 antibodies to ensure optimal performance in their specific experimental systems. The epitope specificity should be carefully considered, with preference given to antibodies targeting functionally relevant domains such as the residues 77-113 or 144-151 regions when studying viral interactions, or antibodies recognizing conserved regions when broader detection across species is required . The species reactivity profile is particularly important since significant structural differences exist between human and mouse SCARB2 that affect both antibody binding and functional studies; this is exemplified by antibodies like JL2 that bind human but not mouse SCARB2 due to a single amino acid difference (R77 in human vs. Q77 in mouse) . The validated applications for each antibody should align with the intended experimental techniques, noting that while Western blot is commonly used, applications like immunohistochemistry, ELISA, and flow cytometry may require antibodies specifically validated for those methods . The clonality (monoclonal versus polyclonal) affects specificity and reproducibility; monoclonal antibodies like JL2 offer high specificity for particular epitopes and consistent performance across experiments, while polyclonal antibodies may provide higher sensitivity at the cost of potential cross-reactivity . Finally, researchers should seek antibodies with documented functional effects (such as viral inhibition capabilities) when conducting mechanistic studies rather than merely detecting protein presence .

How should researchers validate SCARB2 antibodies before use in critical experiments?

Thorough validation of SCARB2 antibodies is essential to ensure experimental rigor and reproducibility in research applications. Researchers should begin with knockout/knockdown controls by testing antibody specificity using SCARB2-knockout cell lines (like the 293-SCARB2-KO model described in the literature) to confirm absence of signal in these negative controls . Overexpression systems, such as 293-hSCARB2 stable cell lines, should be employed as positive controls to demonstrate specific detection of the target protein when expressed at higher-than-normal levels . Cross-species reactivity testing is particularly important for SCARB2 antibodies given the documented differences between human and mouse variants; researchers should explicitly verify whether their antibody detects one or both species, as this affects experimental design and interpretation . Dose-response characterization should be performed by testing antibodies across a concentration range (e.g., from 0.01 μg/mL to saturation around 2 μg/mL) to determine optimal working concentrations and assess binding affinity . Finally, comparative analysis with commercial reference antibodies provides additional validation; for example, the literature mentions that while JL2 is human-specific, the commercial polyclonal antibody Human LIMPII/SR-B2 Antibody (AF1966) recognizes both human and mouse variants, making it useful as a reference standard .

What techniques can determine if SCARB2 antibodies recognize native versus denatured protein conformations?

Determining whether SCARB2 antibodies recognize native or denatured protein conformations is crucial for selecting appropriate applications and interpreting results accurately. Flow cytometry with live cells represents a primary method for assessing binding to native SCARB2, as demonstrated with JL2 antibody which successfully binds surface-expressed SCARB2 on non-permeabilized 293-hSCARB2 cells, confirming recognition of the native conformation . Comparative Western blot analysis under reducing versus non-reducing conditions can reveal conformation-dependent binding; antibodies recognizing linear epitopes typically maintain reactivity under reducing conditions while those targeting conformational epitopes may show diminished binding when disulfide bonds are disrupted . Immunoprecipitation (IP) experiments provide further evidence of native structure recognition, as successful pulldown of SCARB2 from cell lysates prepared under non-denaturing conditions indicates the antibody can bind the protein in its folded state . Enzyme-linked immunosorbent assays (ELISA) using purified SCARB2 protein in various buffer conditions (native versus denaturing) offer a quantitative approach to measure conformation-dependent binding . Structural analysis through techniques such as the crystallography approach used for the SCARB2-JL2 complex can definitively identify the conformational epitopes involved in antibody binding, as was shown for JL2 which contacts α-helices 2, 5, and 14 in the native SCARB2 structure .

How can chimeric SCARB2 constructs be used with antibodies to map functional epitopes?

Chimeric SCARB2 constructs provide powerful tools for mapping functional epitopes when used in combination with specific antibodies. Researchers can generate systematic chimeras by exchanging segments between human and mouse SCARB2 sequences, as demonstrated in the literature where multiple human-mouse chimeric proteins were created to narrowly define the binding regions for the JL2 antibody . A comprehensive chimera panel should include sequential domain swaps progressing from N-terminus to C-terminus (e.g., human 1-76, 77-113, 144-151, 302-478) to systematically narrow down regions contributing to antibody binding or functional differences . Flow cytometry provides a quantitative readout for antibody binding to these chimeras when expressed on the cell surface, allowing researchers to identify which human SCARB2 segments confer binding capability to otherwise non-binding mouse SCARB2 backbone constructs . This approach successfully identified that residues 77-113 of human SCARB2 contribute significantly to JL2 binding, while combination chimeras containing residues 144-151 plus 302-478 from human SCARB2 showed weak binding, suggesting these regions may cooperatively influence protein folding . The chimeric construct approach can be further refined by introducing point mutations within identified regions, as exemplified by the identification of R77 as a potentially critical residue that differs between human (R77) and mouse (Q77) SCARB2 and may account for species-specific antibody binding .

What strategies can researchers employ to develop function-blocking SCARB2 antibodies?

Developing function-blocking SCARB2 antibodies requires strategic immunization and screening approaches targeting functionally relevant epitopes. Researchers should design immunization strategies using full-length human SCARB2 expressed in mammalian cells (as demonstrated with the L929 cell transfection system) to ensure proper protein folding and post-translational modifications critical for generating antibodies against native conformations . The screening methodology should incorporate functional assays rather than mere binding tests; specifically, researchers can develop high-throughput infection inhibition assays using EV71 susceptible cells to identify antibody clones that block viral entry and infection . Epitope focusing techniques can enhance success rates by immunizing with specific SCARB2 domains known to be involved in viral interactions, particularly targeting the apical region containing α-helices that participate in EV71 binding . Strategic hybridoma selection requires multiple rounds of subcloning (4 rounds were used for JL2 development) to ensure monoclonality and stable antibody production before proceeding to ascites generation and antibody purification . Validation of blocking function should include dose-response experiments measuring inhibition of viral infection, as well as mechanistic studies to determine whether the antibody blocks virus binding, internalization, or the uncoating process that occurs at low pH in endosomes .

How can researchers design experiments to distinguish between different mechanisms of antibody-mediated inhibition of EV71 infection?

Designing experiments to distinguish between different mechanisms of antibody-mediated inhibition requires multiple complementary approaches targeting specific stages of viral infection. Binding competition assays using labeled virus particles or viral proteins can determine whether antibodies like JL2 directly compete with EV71 for the same binding site on SCARB2, which would support a direct blocking mechanism of inhibition . Internalization assays employing fluorescently-labeled virus can assess whether antibody-bound SCARB2 can still mediate viral endocytosis, helping to distinguish between inhibition of attachment versus internalization mechanisms . pH-dependent uncoating experiments are particularly important since SCARB2 facilitates EV71 uncoating at low pH; researchers can use antibodies in conjunction with controlled pH changes to determine if the antibody prevents the conformational changes in SCARB2 that normally facilitate uncoating . Time-of-addition experiments, where antibodies are added at different time points relative to viral infection, can help pinpoint which stage of viral entry is affected; inhibition occurring only when antibodies are added before or during viral attachment suggests a different mechanism than inhibition that remains effective after internalization . Structural studies, such as those performed with the SCARB2-JL2 complex, provide the most definitive evidence for mechanism by revealing precisely how antibody binding affects receptor conformation or occludes virus-binding surfaces .

What are common challenges in SCARB2 immunodetection and how can they be addressed?

Researchers frequently encounter several technical challenges when working with SCARB2 antibodies that require specific optimization strategies. Glycosylation heterogeneity presents a significant challenge as SCARB2 undergoes extensive post-translational modifications that can affect antibody recognition; this can be addressed by comparing detection patterns in samples treated with glycosidases or using antibodies specifically validated for recognizing glycosylated forms . Lysosomal localization of SCARB2 can complicate immunofluorescence detection due to the acidic environment and potential degradation of epitopes; researchers can improve detection by optimizing fixation methods, using antigen retrieval techniques, and selecting antibodies that target preserved regions of the protein . Species-specific variations represent another major challenge, as exemplified by the differential binding of JL2 to human but not mouse SCARB2; researchers should carefully validate antibodies across species when conducting comparative studies or using animal models . Signal specificity concerns can be addressed through proper experimental controls, including SCARB2 knockout cells (like the 293-SCARB2-KO line) as negative controls and overexpression systems (such as 293-hSCARB2) as positive controls to confirm antibody specificity . Membrane protein solubilization issues may occur during sample preparation for Western blotting or immunoprecipitation; these can be mitigated by testing different detergent combinations and concentrations to efficiently extract SCARB2 while preserving antibody-recognizable epitopes .

How can researchers troubleshoot inconsistent results when using SCARB2 antibodies across different cell types?

Inconsistent SCARB2 antibody results across different cell types often stem from biological and technical variables that require systematic troubleshooting approaches. Expression level variability represents a primary consideration, as SCARB2 expression differs significantly between tissues and cell types; researchers should normalize detection methods based on known expression patterns or use quantitative approaches like qPCR to correlate antibody signal with actual expression levels . Glycosylation pattern differences between cell types can affect epitope accessibility; comparing treatments with various glycosidases or using multiple antibodies targeting different epitopes can help identify whether post-translational modifications are causing inconsistencies . Subcellular localization shifts may occur between cell types, with SCARB2 predominantly in lysosomes in some cells while showing significant surface expression in others; researchers should optimize permeabilization protocols and potentially use cell fractionation to ensure consistent access to the protein . Protocol optimization should include systematic testing of fixation methods, antibody concentrations, incubation times, and detection systems specifically optimized for each cell type rather than applying a universal protocol . Cross-reactivity with related proteins may occur in cells expressing high levels of SCARB family members; specificity can be confirmed through siRNA knockdown of SCARB2 in each cell type to verify signal reduction, or through parallel testing with knockout/overexpression controls .

What strategies can resolve epitope masking issues in fixed tissue samples when using SCARB2 antibodies?

Epitope masking in fixed tissue samples presents a particular challenge for SCARB2 immunodetection that can be addressed through several specialized techniques. Antigen retrieval optimization represents the frontline approach, with researchers needing to systematically compare heat-induced epitope retrieval methods using different buffer compositions (citrate, EDTA, or Tris-based) and pH conditions to determine which best exposes SCARB2 epitopes without causing tissue degradation . Fixation protocol modifications can significantly impact epitope preservation; researchers should compare results across paraformaldehyde, formalin, and alcohol-based fixatives, with careful attention to fixation duration which can cause progressive epitope masking if too prolonged . Sequential immunostaining strategies can overcome masking issues by performing initial detection with antibodies targeting accessible epitopes, followed by additional retrieval steps to expose masked epitopes for subsequent detection rounds . Antibody panel approaches using multiple antibodies targeting different SCARB2 epitopes in parallel sections can provide complementary data and overcome the limitations of any single antibody's susceptibility to masking effects . Signal amplification techniques, including tyramide signal amplification, polymer-based detection systems, or fluorescent probes with enhanced brightness, can help detect partially masked epitopes that would otherwise produce signals too weak for standard methods .

How might new SCARB2 antibody development advance therapeutic approaches for EV71 infections?

The development of next-generation SCARB2 antibodies holds significant promise for advancing therapeutic approaches against EV71 infections through several innovative strategies. Humanized blocking antibodies derived from murine antibodies like JL2 could be developed through antibody engineering to maintain viral inhibition properties while reducing immunogenicity, creating potential therapeutic candidates for severe EV71 infections that currently lack specific treatments . Bispecific antibody approaches could simultaneously target SCARB2 and viral capsid proteins, potentially creating synergistic blocking effects that prevent viral binding through dual mechanisms and reduce the likelihood of viral escape mutants . Fragment-based therapeutics utilizing smaller antibody fragments (Fab, scFv) derived from SCARB2-binding regions could offer improved tissue penetration while maintaining blocking function, potentially enabling better access to central nervous system tissues affected in severe EV71 infections . Structure-guided optimization based on the elucidated SCARB2-JL2 complex could enable rational design of antibodies with enhanced blocking properties targeting the precise interfaces involved in virus-receptor interactions, particularly focusing on the α-helices 2, 5, and 14 in the apical region of SCARB2 . Antibody-drug conjugates could combine the targeting specificity of SCARB2 antibodies with antiviral payload delivery, potentially creating therapeutic agents that not only block viral entry but also deliver compounds that inhibit viral replication in already infected cells .

What novel applications are emerging for SCARB2 antibodies in neurological disease research?

SCARB2 antibodies are finding expanding applications in neurological disease research beyond their established role in viral pathogenesis studies. Epilepsy mechanism investigations represent a promising frontier, as SCARB2 gene mutations have been associated with progressive myoclonic epilepsy (EPM4); antibodies can help characterize the altered protein localization, trafficking, or interactions in patient-derived samples or model systems expressing disease-associated variants . Lysosomal storage disorder research benefits from SCARB2 antibodies, particularly for studying Gaucher disease mechanisms, since SCARB2 functions as a receptor for glucosylceramidase (GBA1); antibodies can reveal how defects in this trafficking pathway contribute to enzyme mislocalization and substrate accumulation . Neuroinflammation studies can utilize SCARB2 antibodies to investigate potential roles in glial cell activation and inflammatory responses within the central nervous system during viral infections or other inflammatory conditions . Blood-brain barrier models incorporating SCARB2 antibodies can help elucidate whether this protein plays a role in EV71 neuroinvasion by examining receptor expression and function in brain endothelial cells and how this might facilitate viral crossing into neural tissues . Neurodevelopmental studies may benefit from SCARB2 antibodies to track expression patterns during different developmental stages and in various neural cell types, potentially revealing previously unrecognized roles in neurite outgrowth, synapse formation, or circuit development .

How can structural information from SCARB2-antibody complexes inform rational antibody engineering?

Structural information obtained from SCARB2-antibody complexes provides a foundation for rational antibody engineering strategies with enhanced specificities and functions. Epitope-focused optimization can utilize the precise binding interfaces identified in structures like the SCARB2-JL2 complex to design antibodies with complementarity-determining regions (CDRs) specifically tailored to engage critical residues in the target binding site, such as those in α-helices 2, 5, and 14 of SCARB2 . Affinity maturation guided by structural data allows for targeted amino acid substitutions in antibody variable regions that enhance binding energy without altering epitope specificity, potentially improving sensitivity for detection applications or potency for blocking functions . Species cross-reactivity engineering becomes possible when structures reveal the molecular basis for species-specificity, such as the R77 residue in human versus Q77 in mouse SCARB2; rational modifications can create antibodies that either maintain strict species-specificity or gain cross-reactivity as needed for particular research applications . pH-dependent binding engineering can leverage structural insights to create antibodies with modified binding properties at different pH values, which could be particularly valuable for SCARB2 given its involvement in pH-dependent viral uncoating processes in endosomes . Functional domain targeting can be enhanced through structure-guided design of antibodies specifically engineered to bind and modulate critical functional regions, such as those involved in ligand binding or conformational changes, potentially creating more effective research tools and therapeutic candidates .